ClinicalTrials.Veeva

Menu

Multiple Ascending Dose Noribogaine PK/PD in Healthy Volunteers

D

DemeRx NB

Status and phase

Enrolling
Phase 1

Conditions

Pharmacokinetics

Treatments

Drug: Noribogaine

Study type

Interventional

Funder types

Industry

Identifiers

NCT06480981
DMX-NB-001

Details and patient eligibility

About

This trial will be a randomised, double-blind, sequential-group, multiple-dose, placebo-controlled, dose escalation trial to characterise the pharmacokinetics (PK), pharmacodynamics (PD) and safety of noribogaine in healthy adult participants.

Enrollment

60 estimated patients

Sex

All

Ages

18 to 45 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Ability to provide written, personally signed, and dated informed consent.
  • Healthy male and female participants between the ages of 18 to 45 inclusive.
  • BMI 18 - 30 kg/m2.
  • Non- or ex-smoker.
  • Normal ECG findings i.e. QTcF interval ≤ 450 ms and normal morphology that would permit accurate assessment of the QT interval.
  • Participants must agree to use highly

Exclusion criteria

  • History of, or concurrent clinically significant cardiovascular, dysautonomia, gastrointestinal, renal, hepatic, neurologic, hematologic, endocrine, oncologic, pulmonary, immunologic or psychiatric, or any other condition which, in the opinion of the Investigator, would jeopardize the safety of the participant or impact the validity of the study.
  • Family history in first degree relatives for unknown and/or known arrhythmia-related cardiac events, cardiomyopathy, syncope, long QT syndrome, Brugada's syndrome, sudden death attributed to cardiac causes, and familial cardiac channelopathies.
  • Any clinically important abnormalities in rhythm, conduction or morphology of resting ECG that may interfere with interpretation of QTc interval changes.
  • Previous or current alcohol, or other drug dependence.

Trial design

Primary purpose

Other

Allocation

Randomized

Interventional model

Sequential Assignment

Masking

Triple Blind

60 participants in 4 patient groups

Noribogaine 20mg
Experimental group
Description:
1 x Noribogaine 10mg capsule twice daily
Treatment:
Drug: Noribogaine
Noribogaine 40mg
Experimental group
Description:
1 x Noribogaine 20mg capsule twice daily
Treatment:
Drug: Noribogaine
Noribogaine 60mg
Experimental group
Description:
1 x Noribogaine 10mg capsule and 1 x Noribogaine 20mg capsule twice daily
Treatment:
Drug: Noribogaine
Noribogaine 80mg
Experimental group
Description:
2 x Noribogaine 20mg capsule twice daily
Treatment:
Drug: Noribogaine

Trial contacts and locations

1

Loading...

Central trial contact

Jorg Taubel

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems